Affiliations: Department of Laboratory Center, The Affiliated People's Hospital of Jiangsu University, Zhenjiang 212002, Jiangsu, China
Correspondence:
[*]
Corresponding author: Zhao-Qun Deng, Department of Laboratory Center, The Affiliated People's Hospital of Jiangsu University, 8 Dianli Road, Zhenjiang 212002, Jiangsu, China. Tel.: +86 511 88915586; Fax: +86 511 85234387; E-mail:[email protected]
Abstract: OBJECTIVES: This study was intended to investigate the
expression status of Vimentin 2p (VIM 2p), a pseudogene of Vimentin, and further analyze its clinical
significance in AML patients. METHODS: Real-time quantitative PCR (RQ-PCR) was employed
to explore the expression status of VIM 2p in 128 patients with de novo AML and 36
healthy controls. RESULTS: The expression level of VIM 2p was significantly decreased
compared with healthy controls (P< 0.001). The patients with low VIM 2p expression
were identified in 93 of 128 (73%) of AML patients. No
significant differences could be observed in sex, age, blood parameters,
FAB/WHO subtypes, karyotype risks and ten gene mutations (FLT3-ITD, NPM1, C-KIT, IDH1/IDH2, DNMT3 A, C/EBPA, N/K-RAS and U2AF1) between VIM 2p
low-expressed and high-expressed patients (P> 0.05). Patients with
low VIM 2p expression had significantly shorter overall survival (OS) than those
with high VIM 2p expression in whole AML cases (median 7 vs. 13 months,
respectively, P= 0.032), besides cytogenetically normal AML (CN-AML) and
non-M3 AML cohort (P= 0.042 and 0.045, respectively). CONCLUSIONS: These findings indicate that VIM 2p down-regulation
is a common event in AML and may be associated with poor clinical outcome.
